CVIT Expert Consensus Document on Primary Percutaneous Coronary Intervention (PCI) for Acute Coronary Syndromes (ACS) in 2024

Primary Percutaneous Coronary Intervention (PCI) has significantly contributed to reducing the mortality of patients with ST-segment elevation myocardial infarction (STEMI) even in cardiogenic shock and is now the standard of care in most of Japanese institutions. The Task Force on Primary PCI of the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT) proposed an expert consensus document for the management of acute myocardial infarction (AMI) focusing on procedural aspects of primary PCI in 2018 and updated in 2022. Recently, the European Society of Cardiology (ESC) published the guidelines for the management of acute coronary syndrome in 2023. Major new updates in the 2023 ESC guideline include: (1) intravascular imaging should be considered to guide PCI (Class IIa); (2) timing of complete revascularization; (3) antiplatelet therapy in patient with high-bleeding risk. Reflecting rapid advances in the field, the Task Force on Primary PCI of the CVIT group has now proposed an updated expert consensus document for the management of ACS focusing on procedural aspects of primary PCI in 2024 version.

Citing Articles

Current situation and overview of resorbable magnesium scaffolds: a perspective for overcoming the remaining issues of polymeric bioresorbable scaffold.

Seguchi M, Sakakura K, Taniguchi Y, Fujita H Cardiovasc Interv Ther. 2024; 40(2):245-254.

PMID: 39707057 DOI: 10.1007/s12928-024-01070-w.

References

Murai T, Yonetsu T, Kanaji Y, Usui E, Hoshino M, Hada M . Prognostic value of the index of microcirculatory resistance after percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome. Catheter Cardiovasc Interv. 2018; 92(6):1063-1074. DOI: 10.1002/ccd.27529. View

Chichareon P, Modolo R, Collet C, Tenekecioglu E, Vink M, Oh P . Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2019; 74(21):2572-2584. DOI: 10.1016/j.jacc.2019.09.038. View

Mol J, Volleberg R, Belkacemi A, Hermanides R, Meuwissen M, Protopopov A . Fractional Flow Reserve-Negative High-Risk Plaques and Clinical Outcomes After Myocardial Infarction. JAMA Cardiol. 2023; 8(11):1013-1021. PMC: 10500430. DOI: 10.1001/jamacardio.2023.2910. View

Isshiki T, Kozuma K, Kyono H, Suzuki N, Yokoyama N, Yamamoto Y . Initial clinical experience with distal embolic protection using "Filtrap", a novel filter device with a self-expandable spiral basket in patients undergoing percutaneous coronary intervention. Cardiovasc Interv Ther. 2013; 26(1):12-7. DOI: 10.1007/s12928-010-0027-y. View

Kini A, Motoyama S, Vengrenyuk Y, Feig J, Pena J, Baber U . Multimodality Intravascular Imaging to Predict Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2015; 8(7):937-45. DOI: 10.1016/j.jcin.2015.03.016. View

Nijssen E, Rennenberg R, Nelemans P, Essers B, Janssen M, Vermeeren M . Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017; 389(10076):1312-1322. DOI: 10.1016/S0140-6736(17)30057-0. View

Yoshikawa Y, Shiomi H, Watanabe H, Natsuaki M, Kondo H, Tamura T . Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies. Circulation. 2017; 137(6):551-562. DOI: 10.1161/CIRCULATIONAHA.117.028924. View

Moller J, Engstrom T, Jensen L, Eiskjaer H, Mangner N, Polzin A . Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med. 2024; 390(15):1382-1393. DOI: 10.1056/NEJMoa2312572. View

Muramatsu T, Kozuma K, Tsukahara R, Ito Y, Fujita N, Suwa S . Comparison of myocardial perfusion by distal protection before and after primary stenting for acute myocardial infarction: angiographic and clinical results of a randomized controlled trial. Catheter Cardiovasc Interv. 2007; 70(5):677-82. DOI: 10.1002/ccd.21190. View

10.

Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Nishikawa R . Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2023; 83(1):17-31. DOI: 10.1016/j.jacc.2023.10.013. View

11.

Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P . Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based.... Eur Heart J. 2019; 40(46):3757-3767. DOI: 10.1093/eurheartj/ehz732. View

12.

Gragnano F, Cao D, Pirondini L, Franzone A, Kim H, von Scheidt M . P2Y Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. J Am Coll Cardiol. 2023; 82(2):89-105. DOI: 10.1016/j.jacc.2023.04.051. View

13.

Vranckx P, Frigoli E, Rothenbuhler M, Tomassini F, Garducci S, Ando G . Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. Eur Heart J. 2017; 38(14):1069-1080. DOI: 10.1093/eurheartj/ehx048. View

14.

Degertekin M, Serruys P, Tanabe K, Lee C, Sousa J, Colombo A . Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis. Circulation. 2003; 108(22):2747-50. DOI: 10.1161/01.CIR.0000103666.25660.77. View

15.

Mehran R, Baber U, Sharma S, Cohen D, Angiolillo D, Briguori C . Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019; 381(21):2032-2042. DOI: 10.1056/NEJMoa1908419. View

16.

Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R . An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial. Circulation. 2023; 149(8):585-600. DOI: 10.1161/CIRCULATIONAHA.123.066720. View

17.

Pilgrim T, Heg D, Roffi M, Tuller D, Muller O, Vuilliomenet A . Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet. 2014; 384(9960):2111-22. DOI: 10.1016/S0140-6736(14)61038-2. View

18.

Schupke S, Neumann F, Menichelli M, Mayer K, Bernlochner I, Wohrle J . Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019; 381(16):1524-1534. DOI: 10.1056/NEJMoa1908973. View

19.

Nakamura M, Kadota K, Takahashi A, Kanda J, Anzai H, Ishii Y . Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1-Year Results of the PENDULUM Registry. J Am Heart Assoc. 2020; 9(10):e015439. PMC: 7660889. DOI: 10.1161/JAHA.119.015439. View

20.

Engstrom T, Kelbaek H, Helqvist S, Hofsten D, Klovgaard L, Holmvang L . Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015; 386(9994):665-71. DOI: 10.1016/s0140-6736(15)60648-1. View